Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-003-BLD + Gem/Cis in Muscle-Invasive Bladder Cancer
NCT02944357Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Nov 2016
- Primary completion
- Sep 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rocapuldencel-T in muscle-invasive bladder cancer (MIBC), sponsored by Mayo Clinic. Primary endpoint: Change in the frequency of CD11a high PD-1+ CD8+ T cells. Planned start Nov 2016; status: withdrawn.
02
Drugs
rocapuldencel-T
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT02944357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944357.